Alcon Dirección

Dirección controles de criterios 3/4

El CEO de Alcon's es David Endicott , nombrado en Jul 2018, tiene una permanencia de 5.75 años. compensación anual total es $10.39M, compuesta por 11.9% salario y 88.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.047% de las acciones de la empresa, por valor de CHF16.96M. La antigüedad media del equipo directivo y de la junta directiva es de 5 años y 5.3 años, respectivamente.

Información clave

David Endicott

Chief Executive Officer (CEO)

US$10.4m

Compensación total

Porcentaje del salario del CEO	11.9%
Permanencia del CEO	5.8yrs
Participación del CEO	0.05%
Permanencia media de la dirección	5yrs
Promedio de permanencia en la Junta Directiva	5.3yrs

Actualizaciones recientes de la dirección

Recent updates

Alcon Inc.'s (VTX:ALC) Shareholders Might Be Looking For Exit

Apr 03

Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors

Mar 21

Results: Alcon Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 01

There's Been No Shortage Of Growth Recently For Alcon's (VTX:ALC) Returns On Capital

Feb 13

Does Alcon (VTX:ALC) Have A Healthy Balance Sheet?

Dec 28

We Like These Underlying Return On Capital Trends At Alcon (VTX:ALC)

Oct 26

Does Alcon (VTX:ALC) Have A Healthy Balance Sheet?

Sep 15

Alcon's (VTX:ALC) Robust Earnings Are Supported By Other Strong Factors

Aug 24

Is Alcon (VTX:ALC) A Risky Investment?

Jun 11

Alcon Inc. (VTX:ALC) On The Verge Of Breaking Even

May 16

Analyst Estimates: Here's What Brokers Think Of Alcon Inc. (VTX:ALC) After Its Annual Report

Feb 25

Is Alcon (VTX:ALC) A Risky Investment?

Feb 11

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de David Endicott en comparación con los beneficios de Alcon?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	US$974m
Sep 30 2023	n/a	n/a	US$450m
Jun 30 2023	n/a	n/a	US$362m
Mar 31 2023	n/a	n/a	US$341m
Dec 31 2022	US$10m	US$1m	US$335m
Sep 30 2022	n/a	n/a	US$571m
Jun 30 2022	n/a	n/a	US$457m
Mar 31 2022	n/a	n/a	US$460m
Dec 31 2021	US$11m	US$1m	US$376m
Sep 30 2021	n/a	n/a	US$332m
Jun 30 2021	n/a	n/a	US$183m
Mar 31 2021	n/a	n/a	-US$390m
Dec 31 2020	US$8m	US$1m	-US$531m
Sep 30 2020	n/a	n/a	-US$717m
Jun 30 2020	n/a	n/a	-US$636m
Mar 31 2020	n/a	n/a	-US$604m
Dec 31 2019	US$7m	US$1m	-US$656m

Compensación vs. Mercado: La compensación total de David($USD10.39M) está por encima de la media de empresas de tamaño similar en el mercado Swiss ($USD6.42M).

Compensación vs. Ingresos: La compensación de David ha sido consistente con los resultados de la empresa en el último año.

CEO

David Endicott (58 yo)

5.8yrs

Permanencia

US$10,392,671

Compensación

Mr. David J. Endicott is President and Chief Executive Officer at Aerie Pharmaceuticals, Inc. since November 21, 2022. He had been the Chief Executive Officer of Alcon, Inc. since July 1, 2018. He is the C...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
F. Ball	Executive Chairman	5.3yrs	US$1.17m	0.011% $ 4.0m
Arthur Cummings	Executive Director	no data	US$284.68k	0.0012% $ 413.8k
David Endicott	CEO & Director	5.8yrs	US$10.39m	0.047% $ 16.6m
Timothy Stonesifer	Chief Financial Officer	5yrs	sin datos	0.020% $ 6.9m
Margaret Buckley	Chief Accounting Officer	no data	sin datos	sin datos
Franck Leveiller	Senior VP	1.8yrs	sin datos	sin datos
Sue-Jean Lin	Senior VP and Chief Information & Transformation Officer	no data	sin datos	0.0098% $ 3.4m
Royce Bedward	Senior VP	no data	sin datos	sin datos
Kimberly Martin	Senior VP	3.8yrs	sin datos	sin datos
Laurent Attias	Head of Corporate Development	no data	sin datos	0.0040% $ 1.4m
Leon Sergio Fraustro	President of North America	8.7yrs	sin datos	0.0043% $ 1.5m
Ed McGough	Senior VP and Head of Global Manufacturing & Technical Operations	no data	US$2.03m	sin datos

5.0yrs

Permanencia media

57.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ALC es experimentado (5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
F. Ball	Executive Chairman	5.3yrs	US$1.17m	0.011% $ 4.0m
Arthur Cummings	Executive Director	5.3yrs	US$284.68k	0.0012% $ 413.8k
David Endicott	CEO & Director	5.3yrs	US$10.39m	0.047% $ 16.6m
Karen May	Independent Director	5.3yrs	US$325.52k	0.0052% $ 1.8m
D. Grossman	Independent Vice Chair	5.3yrs	US$329.86k	0.0031% $ 1.1m
Thomas Glanzmann	Independent Director	5.3yrs	US$352.98k	0.0041% $ 1.5m
Dieter Spälti	Independent Director	5.3yrs	US$281.62k	0.0049% $ 1.7m
Scott Maw	Independent Director	5.3yrs	US$295.83k	0.0031% $ 1.1m
Lynn Bleil	Independent Director	5.3yrs	US$296.31k	0.0020% $ 687.4k
Ines Pöschel	Independent Director	5.3yrs	US$293.86k	0.0021% $ 747.0k
RaQuel Bono	Independent Director	2yrs	US$256.66k	0.00057% $ 199.9k

5.3yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de ALC se considera experimentada (5.3 años de antigüedad promedio).

Alcon Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Alcon Announces Management Changes

President of North America notifies of intention to sell stock

Alcon Inc., Annual General Meeting, May 08, 2024

Head of Corporate Development notifies of intention to sell stock

Alcon Inc., Annual General Meeting, May 05, 2023

Insufficient new directors

Recent updates

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and Its Hydrus Microstent for Microinvasive Glaucoma Surgery

Dividend of CHF0.24 announced

Alcon Inc.'s (VTX:ALC) Shareholders Might Be Looking For Exit

Alcon Announces Management Changes

Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors

Alcon Inc. Launches Clareon Presbyopia Correcting IOLs in India

President of North America notifies of intention to sell stock

Results: Alcon Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Alcon Inc. Proposes Dividend for the Year 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Alcon Announces Positive Topline Results from Phase 3 Comet Trials of AR-15512, A Novel Topical Drug Candidate for Dry Eye

Alcon Inc.'s (VTX:ALC) Business Is Yet to Catch Up With Its Share Price

Returns On Capital Are Showing Encouraging Signs At Alcon (VTX:ALC)

Alcon Inc., Annual General Meeting, May 08, 2024

Alcon Inc. Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Calculating The Fair Value Of Alcon Inc. (VTX:ALC)

Alcon Inc. Showcases Cloud-Based Planning and World-Class Digital Technologies During AAO 2023

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Alcon Launches Total30 Multifocal Contact Lenses for Patients with Presbyopia

Alcon (VTX:ALC) Might Have The Makings Of A Multi-Bagger

Alcon Inc. Raises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.30 in 2Q 2022)

A Look At The Fair Value Of Alcon Inc. (VTX:ALC)

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Head of Corporate Development notifies of intention to sell stock

Investors Will Want Alcon's (VTX:ALC) Growth In ROCE To Persist

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alcon Inc. Provides Earnings Guidance for the Year 2023

Alcon Announces Results from a New Study Presented at the American Society of Cataract and Refractive Surgery Annual Meeting

Alcon Inc. Approves Dividend

Upcoming dividend of CHF0.21 per share at 0.3% yield

Does Alcon (VTX:ALC) Have A Healthy Balance Sheet?

Full year 2022 earnings: EPS misses analyst expectations

Now 21% undervalued

Alcon Inc. Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices

Alcon Launches New Total Toric Lenses for Astigmatic Patients

Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors

Returns Are Gaining Momentum At Alcon (VTX:ALC)

Alcon Inc., Annual General Meeting, May 05, 2023

Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Now 20% undervalued

Alcon Inc. Updates Earnings Guidance for the Year 2022

Insufficient new directors

Alcon Inc. Revises Revenue Guidance for 2022

Do Alcon's (VTX:ALC) Earnings Warrant Your Attention?

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

Alcon's (VTX:ALC) Returns On Capital Are Heading Higher

We Think Alcon (VTX:ALC) Can Stay On Top Of Its Debt

With Alcon Inc. (VTX:ALC) It Looks Like You'll Get What You Pay For

Alcon Inc. (SWX:ALC) entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) for approximately $770 million.

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations

Alcon Inc. Revises Revenue Guidance for 2022

These 4 Measures Indicate That Alcon (VTX:ALC) Is Using Debt Reasonably Well

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

Alcon (VTX:ALC) Is Experiencing Growth In Returns On Capital

Alcon Inc. Reaffirms Earnings Guidance for the Fiscal 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Alcon Inc. Declares Dividend for 2021

Insufficient new directors

Alcon Announces Key Data to Be Presented at This Year’s American Society of Cataract and Refractive Surgery Meeting on its SMART Solutions for Cataract Surgery

Alcon Inc. Announces Launch of Clareon Portfolio in the U.S

Consensus EPS estimates increase by 12%

Full year 2021 earnings: EPS exceeds analyst expectations

Alcon Inc. Proposes Dividend

There's Been No Shortage Of Growth Recently For Alcon's (VTX:ALC) Returns On Capital